Medicine
Milrinone 1 mg/mL injection
Milrinone 1 mg/mL injection is a generic prescription medicine for intravenous use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Avoid freezing. Store at 20° to 25°C (68° to 77°F). Brief exposure of Flexible…
Key facts
- Active ingredient (INN)
- Milrinone
- Brand
- Sold under the generic name
- Strength
- 1 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 50 mL, 10 boxes
- Manufacturer
- Hikma Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Avoid freezing. Store at 20° to 25°C (68° to 77°F). Brief exposure of Flexible Containers up to 40ºC (104ºF) does not adversely affect the product.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C01CE02 Milrinone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 December 2010
- Identifiers
- RxCUI 1791854, 1791859, 1791861DailyMed set ID 88f78780-399f-4780-be19-205739db1682NDC 0143-9708Application ANDA077966
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 50 mL in 1 box | 0143-9708-01 | Hikma Pharmaceuticals | 3 December 2010 |
| 10 box in 1 box / 50 mL in 1 box | 0143-9708-10 | Hikma Pharmaceuticals | 3 December 2010 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 31 December 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Milrinone
Clinical summary
Milrinone is a phosphodiesterase 3 inhibitor indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. It is available as injection for intravenous use. MedsAcross supplies Milrinone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MilrinoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Milrinone Lactate prescribing information (Mullan Pharmaceutical) · U.S. National Library of Medicine, DailyMed
Need Milrinone 1 mg/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.